The importance of doxorubicin and methotrexate dose intensity in the chemotherapy of osteosarcoma

A. Kawai, S. Sugihara, Toshiyuki Kunisada, M. Hamada, H. Inoue

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The relationship between dose intensity of cytotoxic agents and therapeutic results was examined in a retrospective analysis of 32 patients with non-metastatic high-grade osteosarcoma of the extremities. The average dose intensities of individual agents were 9.8 mg/m2/week for doxorubicin, 1.2 g/m2/week for methotrexate, and 10.5 mg/m2/week for cisplatinum. The dose intensities of doxorubicin and methotrexate were significantly correlated with the clinical results, while that of cisplatinum was not. These results indicate that maximal dose intensification of doxorubicin and methotrexate is an important determinant of treatment outcome for patients with osteosarcoma.

Original languageEnglish
Pages (from-to)68-70
Number of pages3
JournalArchives of Orthopaedic and Trauma Surgery
Volume115
Issue number2
DOIs
Publication statusPublished - Mar 1996

Fingerprint

Osteosarcoma
Methotrexate
Doxorubicin
Drug Therapy
Cytotoxins
Extremities
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

The importance of doxorubicin and methotrexate dose intensity in the chemotherapy of osteosarcoma. / Kawai, A.; Sugihara, S.; Kunisada, Toshiyuki; Hamada, M.; Inoue, H.

In: Archives of Orthopaedic and Trauma Surgery, Vol. 115, No. 2, 03.1996, p. 68-70.

Research output: Contribution to journalArticle

@article{fd5f623b035442d8b62618d2216a057c,
title = "The importance of doxorubicin and methotrexate dose intensity in the chemotherapy of osteosarcoma",
abstract = "The relationship between dose intensity of cytotoxic agents and therapeutic results was examined in a retrospective analysis of 32 patients with non-metastatic high-grade osteosarcoma of the extremities. The average dose intensities of individual agents were 9.8 mg/m2/week for doxorubicin, 1.2 g/m2/week for methotrexate, and 10.5 mg/m2/week for cisplatinum. The dose intensities of doxorubicin and methotrexate were significantly correlated with the clinical results, while that of cisplatinum was not. These results indicate that maximal dose intensification of doxorubicin and methotrexate is an important determinant of treatment outcome for patients with osteosarcoma.",
author = "A. Kawai and S. Sugihara and Toshiyuki Kunisada and M. Hamada and H. Inoue",
year = "1996",
month = "3",
doi = "10.1007/BF00573443",
language = "English",
volume = "115",
pages = "68--70",
journal = "Archiv fur orthopadische und Unfall-Chirurgie",
issn = "0003-9330",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - The importance of doxorubicin and methotrexate dose intensity in the chemotherapy of osteosarcoma

AU - Kawai, A.

AU - Sugihara, S.

AU - Kunisada, Toshiyuki

AU - Hamada, M.

AU - Inoue, H.

PY - 1996/3

Y1 - 1996/3

N2 - The relationship between dose intensity of cytotoxic agents and therapeutic results was examined in a retrospective analysis of 32 patients with non-metastatic high-grade osteosarcoma of the extremities. The average dose intensities of individual agents were 9.8 mg/m2/week for doxorubicin, 1.2 g/m2/week for methotrexate, and 10.5 mg/m2/week for cisplatinum. The dose intensities of doxorubicin and methotrexate were significantly correlated with the clinical results, while that of cisplatinum was not. These results indicate that maximal dose intensification of doxorubicin and methotrexate is an important determinant of treatment outcome for patients with osteosarcoma.

AB - The relationship between dose intensity of cytotoxic agents and therapeutic results was examined in a retrospective analysis of 32 patients with non-metastatic high-grade osteosarcoma of the extremities. The average dose intensities of individual agents were 9.8 mg/m2/week for doxorubicin, 1.2 g/m2/week for methotrexate, and 10.5 mg/m2/week for cisplatinum. The dose intensities of doxorubicin and methotrexate were significantly correlated with the clinical results, while that of cisplatinum was not. These results indicate that maximal dose intensification of doxorubicin and methotrexate is an important determinant of treatment outcome for patients with osteosarcoma.

UR - http://www.scopus.com/inward/record.url?scp=0030033741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030033741&partnerID=8YFLogxK

U2 - 10.1007/BF00573443

DO - 10.1007/BF00573443

M3 - Article

VL - 115

SP - 68

EP - 70

JO - Archiv fur orthopadische und Unfall-Chirurgie

JF - Archiv fur orthopadische und Unfall-Chirurgie

SN - 0003-9330

IS - 2

ER -